Author

Lucy V. Edwardes

Observed name: Lucy Edwardes

Institution: Artios Pharma Limited (United Kingdom)

Observed institutions: AstraZeneca (United Kingdom), MRC London Institute of Medical Sciences, Artios Pharma Limited (United Kingdom), Imperial College London, Medical Research Council

ORCID: 0000-0002-0074-0100

Observed ORCID: 0000-0002-0074-0100

OpenAlex ID: A5046237312

Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta

2022 · Martin L. Stockley, Amanda Ferdinand, et al. · Journal of Medicinal Chemistry · 53

Reconstitution of human DNA licensing and the structural and functional analysis of key intermediates

2025 · Jennifer N. Wells, Lucy V. Edwardes, et al. · Nature Communications · 21

Characterization of the Kinetic Mechanism of Human Protein Arginine Methyltransferase 5

2020 · Alice R. Eddershaw, Christopher J. Stubbs, et al. · Biochemistry · 12

Dissecting the Kinetic Mechanism of Human Lysine Methyltransferase 2D and Its Interactions with the WRAD2 Complex

2022 · Lucy V. Edwardes, Sarah J. Caswell, et al. · Biochemistry · 3

The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy

2026 · Helen M.R. Robinson, Vera Grinkevich, et al. · Clinical Cancer Research · 2

Geminin inhibits DNA replication licensing by sterically blocking CDT1-MCM2 interactions

2025 · Joshua Tomkins, Lucy V. Edwardes, et al. · Nature Communications · 1

Correction to “Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta”

2023 · Martin L. Stockley, Giovanni Benedetti, et al. · Journal of Medicinal Chemistry · 1

Data from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy

2026 · Helen M.R. Robinson, Vera Grinkevich, et al.

Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy

2026 · Helen M.R. Robinson, Vera Grinkevich, et al.

Works count: 9

Citation count: 93

H-index: 3

I10-index: 3